[Data] Companies That Can Use AI and Companies That Cannot: The Productivity Gap That Will Open in Three Years
The battle of "whether to implement it" is already over. An introduction to AI utilization for managers.
This document is intended to provide a numerical perspective on the costs of inaction regarding AI utilization, specifically focusing on the "wait-and-see" approach. Based on publicly available survey data, it organizes the current state and mechanisms of disparity, as well as methods for estimating your company's inaction costs. It is a brief read that can be completed in a few minutes. Please use it as a resource for your company's decision-making. 【Contents】 ■ The gap is quietly widening during the "wait-and-see" period ■ The debate over "whether to implement" is already over ■ The path of "solving by increasing personnel" is becoming closed off ■ How much can productivity actually increase with AI? ■ Why does the gap widen not "uniformly" but "compounded"? *For more details, please download the PDF or feel free to contact us.
Inquire About This Product
basic information
【Other Published Content】 ■What is your company's "cost of neglect"? ■The biggest misconception is "if we distribute the tools, we can catch up." ■Conditions for companies that will win in three years - Three actions you can start this month. *For more details, please download the PDF or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please download the PDF or feel free to contact us.
catalog(1)
Download All CatalogsCompany information
Our company provides the AI agent platform "AI OMNI AGENT." It is not just a generative AI tool; it autonomously performs "understanding → judgment → execution," continuously advancing tasks as a true digital personal assistant, strongly supporting your business. AI reduces labor hours, allowing employees to create value. AI supports all tasks of humans and maximizes the potential for challenges.




![[Case Study] Fortience Consulting Co., Ltd.](https://image.www.ipros.com/public/product/image/2062917/IPROS14429828811621611775.png?w=280&h=280)
![[Rosetta Stone Case Study] Kyoritsu Pharmaceutical Co., Ltd.](https://image.www.ipros.com/public/product/image/2062917/IPROS3038661670244870837.png?w=280&h=280)